|
Dr. Tidmarsh is a pediatric oncologist with nearly twenty years of entrepreneurial and executive experience in biotechnology. He has been involved in numerous successful startups, FDA drug approvals, and IPOšs. Dr. Tidmarsh was the founder of Threshold Pharmaceuticals and from 2001 until Aug. 2005 he served as President. Prior to Threshold, George held various positions at Coulter Pharmaceuticals, Inc., including chief medical officer from September 1998. During that time he played a key role in the landmark $142MM co-development deal with Smith-Kline. Prior to that he held scientific and clinical positions at SEQUUS, Gilead Sciences and SyStemix,Inc. George led fundamental scientific discovery efforts at Systemix and Gilead Sciences and also played a key role at Sequus in the FDA approval process of Doxil including the successful presentation to the FDA Oncology Drug Advisory Committee. He received his M.D. and Ph.D. from the Stanford University School of Medicine where he also completed fellowships in Pediatric Oncology and Neonatal Intensive Care. In addition, he has been a clinical staff member at Stanford Children's Hospital and El Camino Hospital. He is an author of 18 peer-reviewed scientific papers published in leading journals. | 